Related Experiment Video
Updated: Apr 17, 2026
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
[A case report: an EML4-ALK positive lung adenocarcinoma diagnosed with lymphoma previously]
1Department of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Abstract:
In recent years, with the deepening of the research of molecular biology, targeted therapy has become one of the trend of lung cancer treatment. The individualized treatment of lung cancer is attached great importance at present. Echinoderm microtubule associated protein like 4 anaplastic lymphoma kinase (EML4-ALK) as a new biological marker is a hot topic in the field of lung cancer treatment. Meanwhile, with the improvement of anticancer treatment and survival, the incidence of multiple primary carcinomas (MPC) has become increasingly. But the report that malignant lymphoma complicated with lung adenocarcinoma harboring EML4-ALK fusion gene in one individual is rare. Here, we report an EML4-ALK positive non-small cell lung cancer (NSCLC) in a patient previously diagnosed with T cell lymphoma and review literature on metachronous lung cancer complicating with lymphoma.
Insights
This study reports a rare case of non-small cell lung cancer (NSCLC) with an EML4-ALK fusion gene in a patient with a prior T cell lymphoma diagnosis. It highlights the increasing incidence of multiple primary carcinomas and the importance of targeted therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Targeted therapy and individualized treatment are current trends in lung cancer management.
- Echinoderm microtubule associated protein like 4 anaplastic lymphoma kinase (EML4-ALK) fusion gene is a significant biomarker in lung cancer.
- Multiple primary carcinomas (MPC) incidence is rising due to improved cancer treatment and survival rates.
